Natalie Byrne
COPE Galway(IE)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Protein Degradation and Inhibitors, Computational Drug Discovery Methods, Synthesis and biological activity, Advanced Breast Cancer Therapies
Most-Cited Works
- → Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial(2019)2,107 cited
- → Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial(2020)668 cited
- → Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)(2010)261 cited
- → Transmission of Cryptosporidium Species Among Human and Animal Local Contact Networks in Sub-Saharan Africa: A Multicountry Study(2020)53 cited
- → Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.(2020)48 cited
- → Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition(2021)35 cited
- → Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS)(2003)33 cited
- → Contracting for ‘Contextualism’ – How can parties influence the interpretation method applied to their agreement?(2013)31 cited
- → Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial(2023)21 cited
- → PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study(2019)21 cited